Evidence map›Paper›PMID 33768725›Full record

ArticleAngewandte Chemie (International ed. in English)2021

Photochemical Probe Identification of a Small-Molecule Inhibitor Binding Site in Hedgehog Acyltransferase (HHAT)*.

Thomas Lanyon-Hogg, Markus Ritzefeld, Leran Zhang, Sebastian A Andrei, Balazs Pogranyi, Milon Mondal, Lea Sefer, Callum D Johnston, Claire E Coupland, Jake L Greenfield and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Thomas Lanyon-HoggDepartment of Pharmacology, University of Oxford, Oxford, OX1 3QT, UK.ORCID 0000-0002-7092-8096
Markus RitzefeldDepartment of Chemistry, Imperial College London, London, W12 0BZ, UK.ORCID 0000-0002-9898-4110
Leran ZhangDepartment of Chemistry, Imperial College London, London, W12 0BZ, UK.
Sebastian A AndreiDepartment of Chemistry, Imperial College London, London, W12 0BZ, UK.ORCID 0000-0003-2961-8018
Balazs PogranyiDepartment of Chemistry, Imperial College London, London, W12 0BZ, UK.ORCID 0000-0002-9269-4462
Milon MondalDepartment of Chemistry, Imperial College London, London, W12 0BZ, UK.ORCID 0000-0002-1613-7269
Lea SeferDivision of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK.
Callum D JohnstonDepartment of Chemistry, Imperial College London, London, W12 0BZ, UK.ORCID 0000-0002-2507-5530
Claire E CouplandDivision of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK.
Jake L GreenfieldDepartment of Chemistry, Imperial College London, London, W12 0BZ, UK.ORCID 0000-0002-7650-5414
Joshua NewingtonDepartment of Chemistry, Imperial College London, London, W12 0BZ, UK.
Matthew J FuchterDepartment of Chemistry, Imperial College London, London, W12 0BZ, UK.ORCID 0000-0002-1767-7072
Anthony I MageeNational Heart & Lung Institute, Imperial College London, London, SW7 2AZ, UK.
Christian SieboldDivision of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK.ORCID 0000-0002-6635-3621
Edward W TateDepartment of Chemistry, Imperial College London, London, W12 0BZ, UK.ORCID 0000-0003-2213-5814
Imperial College London · GBCentre for Human Genetics · GBLung Institute · USUniversity of Oxford · GB

Funding

Biotechnology and Biological Sciences Research Council BB/T01508X/1Cancer Research UK 16402Cancer Research UK 20183Cancer Research UK 26752Cancer Research UK C20724/A14414Cancer Research UK C20724/A26752Cancer Research UK C29637/A20183Cancer Research UK C6433/A16402Wellcome TrustWellcome Trust 102749/Z/13/ZWellcome Trust BST00110.B500.04
6 · The paper itself

Abstract

The mammalian membrane-bound O-acyltransferase (MBOAT) superfamily is involved in biological processes including growth, development and appetite sensing. MBOATs are attractive drug targets in cancer and obesity; however, information on the binding site and molecular mechanisms underlying small-molecule inhibition is elusive. This study reports rational development of a photochemical probe to interrogate a novel small-molecule inhibitor binding site in the human MBOAT Hedgehog acyltransferase (HHAT). Structure-activity relationship investigation identified single enantiomer IMP-1575, the most potent HHAT inhibitor reported to-date, and guided design of photocrosslinking probes that maintained HHAT-inhibitory potency. Photocrosslinking and proteomic sequencing of HHAT delivered identification of the first small-molecule binding site in a mammalian MBOAT. Topology and homology data suggested a potential mechanism for HHAT inhibition which was confirmed by kinetic analysis. Our results provide an optimal HHAT tool inhibitor IMP-1575 (K

Indexed as

AcetyltransferasesAffinity LabelsBinding SitesHumansKineticsLightPalmitoyl Coenzyme APyridinesSmall Molecule LibrariesStructure-Activity RelationshipAcetyltransferasesAffinity LabelsPalmitoyl Coenzyme APyridinesSmall Molecule LibrariesenzymesHedgehog acyltransferaseHedgehog signallingmembrane-bound O-acyltransferasephotoaffinity labelling

Identifiers

PMID33768725
PMCPMC8252026
OpenAlexW3093450418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.